Distributor inventory
Glimepiride 1 mg + Voglibose 0.3 mg (tablet)
Type 2 diabetes mellitus; used to improve blood sugar control in adults when diet and exercise alone or single therapy is inadequate.
Glimepiride (a sulfonylurea) increases insulin release from the pancreas and improves peripheral glucose utilization. Voglibose (an alpha‑glucosidase inhibitor) delays intestinal carbohydrate digestion and absorption, reducing post‑meal blood glucose spikes.
Take orally as prescribed. Usually taken once daily just before or with the first main meal; swallow whole with water. Do not skip meals after taking; follow diet/exercise plan and monitor blood glucose.
Common side effects of VOGLINORM GM1/0.3 may include:
Risk of hypoglycaemia (higher with missed meals, alcohol, excessive exercise, elderly, renal/hepatic impairment); monitor blood glucose regularly. Use with caution in kidney or liver disease. Not recommended in type 1 diabetes or diabetic ketoacidosis. If severe abdominal pain or persistent GI symptoms occur, seek medical advice. Inform doctor before surgery/acute illness as dose adjustment may be needed.
